Prescribing decisions affected by student interaction with marketers

Article

Medical trainees who spend more time with pharmaceutical marketing representatives are less likely to make evidence-based choices when prescribing, according to a study recently published in JAMA Internal Medicine.

Medical trainees who spend more time with pharmaceutical marketing representatives are less likely to make evidence-based choices when prescribing, according to a study recently published in JAMA Internal Medicine.

Researchers surveyed a randomly selected, nationally representative sample of first- and fourth-year medical students, as well as third-year residents.

Study: 90 percent of health-related Wikipedia articles contain errors

“All trainees were asked how often they used different educational resources to learn about prescription drugs. Among fourth-year students and residents, we posed a series of multiple choice knowledge questions asking about the appropriate initial therapy for clinical scenarios involving patients with diabetes, hyperlipidemia, hypertension, and difficulty sleeping,” the study’s authors say.

Participants were also asked about frequency in the past six months of interactions with the pharmaceutical industry, their expected frequency of interactions in their careers, and their attitudes about such interactions. Researchers used the survey answers to build an industry relations index assessing each trainee’s level of acceptance of pharmaceutical promotion.

The study found that 48 percent to 90 percent of fourth-year students and residents accurately identified evidence-based prescribing choices. According to researchers, a 10-point higher industry relations index was associated with 15 percent lower odds of selecting an evidence-based prescribing choice. The study also found there was a significant association between the industry relations index and greater odds of choosing to prescribe brand-name drugs.

The study also found that the 1601 students and 735 residents who participated reported common use of unfiltered sources of drug information such as Google (74.2 percent to 88.9 percent) and Wikipedia (45.2 percent to 84.5 percent).

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.